Investigator Conflicts of Interest
In compliance with federal law, OMRF discloses that the following investigators possesses financial interests that are related to their federally funded research and that could directly and significantly affect the design, conduct or reporting of that research. OMRF has a conflict management plan in place that provides institutional and independent oversight of the research to ensure that no bias is present.
Robert Axtell, Ph.D.
Significant Financial Interests
- Axtell owns stock options in Progentec Diagnostics, Inc., a privately held biotechnology company developing tests to identify and guide treatment in autoimmune diseases that include neuromyelitis optica. The value of these stock options cannot be readily determined.
- Dr. Axtell serves as a paid a consultant for EMD Serono, which develops and manufactures drugs to treat multiple sclerosis, including an interferon-based drug that is currently on the market. For these services, Dr. Axtell is paid $10,000 to $19,999.
Potentially Affected Federal Grants
Dr. Axtell is the principal investigator on the following National Institutes of Health grants that could be affected by the financial interests listed above:
- Understanding the roles type I interferon and TH17 play in neuromyelitis optica and other autoimmune diseases (R01AI137047)
- Pathogenic B cell and T helper cell interactions in neuromyelitis optica (R01EY027346)